Drug Profile
BTKmt
Alternative Names: BTK-mtLatest Information Update: 22 Aug 2018
Price :
$50
*
At a glance
- Originator X-Rx
- Class Antineoplastics; Small molecules
- Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 22 Aug 2018 Discontinued for Cancer in USA (unspecified route)
- 05 Aug 2016 BTKmt is available for licensing as of 05 Aug 2016. http://www.x-rxdiscovery.com/
- 05 Aug 2016 Early research in Cancer in USA (unspecified route)